Startups.Bio showcases an emerging biotech startup each week, selected by the analyst team at VentureRadar from the 10,000s of companies we track.
NonExomics is focused on the non-exome regions of the genome and has identified hundreds of potential new drug targets across rare diseases, neuropsychiatric disorders, and cancer. The parts of our DNA that code for proteins make up around 2% of the human genome and are collectively known as the exome. The exome is the best […]
We featured eight biotech startups in the last three month of 2021, working on a range new approaches to tackling major diseases. You can find out more about the companies in the summaries below, or go to the VentureRadar Database to find thousands more biotech companies similar to these ones. Resalis Therapeutics Resalis Therapeutics is […]
Amyl Therapeutics is Belgian preclinical biotech company developing a technology platform to bind various types of amyloid fibrils and induce their clearance, potentially offering a breakthrough approach to treating protein misfolding diseases. Amyloidosis is a group of diseases characterized by an endogenous production of misfolded proteins that aggregate as insoluble amyloid fibrils and form deposits […]